Follow
Jillian Clare Kohler
Jillian Clare Kohler
Associate Professor, Leslie Dan Faculty of Pharmacy; Director of Global Health, Munk School of
Verified email at utoronto.ca - Homepage
Title
Cited by
Cited by
Year
How to achieve international action on falsified and substandard medicines
A Attaran, D Barry, S Basheer, R Bate, D Benton, J Chauvin, L Garrett, ...
Bmj 345, 2012
1942012
Medical certification of cause of death: instructions for physicians on use of international form of medical certificate of cause of death
World Health Organization
World Health Organization, 1979
190*1979
The sustainable development goals as a framework to combat health-sector corruption
TK Mackey, T Vian, J Kohler
Bulletin of the World Health Organization 96 (9), 634, 2018
1112018
Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers
HA Garuba, JC Kohler, AM Huisman
Globalization and health 5, 1-13, 2009
1022009
The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk
JC Kohler, D Dimancesco
Global health action 13 (sup1), 1694745, 2020
952020
Benchmarking and transparency: Incentives for the pharmaceutical industry’s corporate social responsibility
M Lee, J Kohler
Journal of Business Ethics 95, 641-658, 2010
922010
Social capital and public health: responding to the COVID-19 pandemic
ASY Wong, JC Kohler
Globalization and health 16 (1), 88, 2020
872020
The disease of corruption: views on how to fight corruption to advance 21st century global health goals
TK Mackey, JC Kohler, WD Savedoff, F Vogl, M Lewis, J Sale, J Michaud, ...
BMC medicine 14, 1-16, 2016
812016
The role of supportive supervision on immunization program outcome-a randomized field trial from Georgia
M Djibuti, G Gotsadze, A Zoidze, G Mataradze, LC Esmail, JC Kohler
BMC international health and human rights 9, 1-12, 2009
802009
Orphan drug policies: implications for the United States, Canada, and developing countries
RY Cheung, JC Cohen, P Illingworth
Health LJ 12, 183, 2004
762004
Global health and human rights in the time of COVID-19: Response, restrictions, and legitimacy
L Forman, JC Kohler
Rights at Stake and the COVID-19 Pandemic, 33-42, 2023
752023
Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance
T Vian, JC Kohler, G Forte, D Dimancesco
Journal of Pharmaceutical Policy and Practice 10, 1-11, 2017
722017
AIDS policy and pharmaceutical patents: Brazil's strategy to safeguard public health
JC Cohen, KM Lybecker
World Economy 28 (2), 211-230, 2005
692005
The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements
JC Cohen, P Illingworth
Developing world bioethics 3 (1), 27-48, 2003
672003
Corruption and pharmaceuticals: Strengthening good governance to improve access
JC Cohen, MF Mrazek, L Hawkins
The Many Faces of Corruption: Tracking Vulnerabilities at the Sector Level …, 2007
652007
The morally uncomfortable global drug gap
JC Cohen‐Kohler
Clinical Pharmacology & Therapeutics 82 (5), 610-614, 2007
642007
Increasing transparency and accountability in national pharmaceutical systems
A Paschke, D Dimancesco, T Vian, JC Kohler, G Forte
Bulletin of the World Health Organization 96 (11), 782, 2018
622018
Corruption in the health care sector: A barrier to access of orthopaedic care and medical devices in Uganda
M Bouchard, JC Kohler, J Orbinski, A Howard
BMC international health and human rights 12, 1-9, 2012
582012
Tackling corruption in the pharmaceutical systems worldwide with courage and conviction
JC Cohen, M Mrazek, L Hawkins
Clinical Pharmacology & Therapeutics 81 (3), 445-449, 2007
572007
Pharmaceuticals and corruption: a risk assessment
JC Cohen
Global corruption report 2006, 77-84, 2006
542006
The system can't perform the operation now. Try again later.
Articles 1–20